378 related articles for article (PubMed ID: 21204741)
21. Current Status on Clinical Development of Adeno-Associated Virus-Mediated Liver-Directed Gene Therapy for Inborn Errors of Metabolism.
Ginocchio VM; Ferla R; Auricchio A; Brunetti-Pierri N
Hum Gene Ther; 2019 Oct; 30(10):1204-1210. PubMed ID: 31517544
[TBL] [Abstract][Full Text] [Related]
22. Designer gene delivery vectors: molecular engineering and evolution of adeno-associated viral vectors for enhanced gene transfer.
Kwon I; Schaffer DV
Pharm Res; 2008 Mar; 25(3):489-99. PubMed ID: 17763830
[TBL] [Abstract][Full Text] [Related]
23. Safety profile of recombinant adeno-associated viral vectors: focus on alipogene tiparvovec (Glybera®).
Salmon F; Grosios K; Petry H
Expert Rev Clin Pharmacol; 2014 Jan; 7(1):53-65. PubMed ID: 24308784
[TBL] [Abstract][Full Text] [Related]
24. Immunity to adeno-associated virus vectors in animals and humans: a continued challenge.
Zaiss AK; Muruve DA
Gene Ther; 2008 Jun; 15(11):808-16. PubMed ID: 18385765
[TBL] [Abstract][Full Text] [Related]
25. Clinical gene therapy using recombinant adeno-associated virus vectors.
Mueller C; Flotte TR
Gene Ther; 2008 Jun; 15(11):858-63. PubMed ID: 18418415
[TBL] [Abstract][Full Text] [Related]
26. AAV-based gene transfer.
Büning H; Nicklin SA; Perabo L; Hallek M; Baker AH
Curr Opin Mol Ther; 2003 Aug; 5(4):367-75. PubMed ID: 14513679
[TBL] [Abstract][Full Text] [Related]
27. The future of epilepsy treatment: focus on adeno-associated virus vector gene therapy.
McCown TJ
Drug News Perspect; 2010 Jun; 23(5):281-6. PubMed ID: 20603651
[TBL] [Abstract][Full Text] [Related]
28. Directed evolution of novel adeno-associated viruses for therapeutic gene delivery.
Bartel MA; Weinstein JR; Schaffer DV
Gene Ther; 2012 Jun; 19(6):694-700. PubMed ID: 22402323
[TBL] [Abstract][Full Text] [Related]
29. Adeno-associated virus as a gene therapy vector: strategies to neutralize the neutralizing antibodies.
Lotfinia M; Abdollahpour-Alitappeh M; Hatami B; Zali MR; Karimipoor M
Clin Exp Med; 2019 Aug; 19(3):289-298. PubMed ID: 31054018
[TBL] [Abstract][Full Text] [Related]
30. In vivo hepatic gene therapy.
Ni YH
Acta Paediatr Taiwan; 2001; 42(4):191-200. PubMed ID: 11550406
[TBL] [Abstract][Full Text] [Related]
31. Adeno-associated virus serotypes: vector toolkit for human gene therapy.
Wu Z; Asokan A; Samulski RJ
Mol Ther; 2006 Sep; 14(3):316-27. PubMed ID: 16824801
[TBL] [Abstract][Full Text] [Related]
32. Adeno-associated virus vectors for gene therapy of neurodegenerative disorders.
During MJ; Leone P
Clin Neurosci; 1995-1996; 3(5):292-300. PubMed ID: 8914796
[TBL] [Abstract][Full Text] [Related]
33. [The development in the studies of AAV-mediated gene therapy in retina].
Zou X; Sui RF; Dong FT
Zhonghua Yan Ke Za Zhi; 2011 Nov; 47(11):1049-52. PubMed ID: 22336072
[TBL] [Abstract][Full Text] [Related]
34. Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors.
Sarukhan A; Camugli S; Gjata B; von Boehmer H; Danos O; Jooss K
J Virol; 2001 Jan; 75(1):269-77. PubMed ID: 11119597
[TBL] [Abstract][Full Text] [Related]
35. Basic biology of adeno-associated virus (AAV) vectors used in gene therapy.
Balakrishnan B; Jayandharan GR
Curr Gene Ther; 2014; 14(2):86-100. PubMed ID: 24588706
[TBL] [Abstract][Full Text] [Related]
36. Strategies to circumvent humoral immunity to adeno-associated viral vectors.
Tse LV; Moller-Tank S; Asokan A
Expert Opin Biol Ther; 2015 Jun; 15(6):845-55. PubMed ID: 25985812
[TBL] [Abstract][Full Text] [Related]
37. Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors.
Raake PW; Hinkel R; Müller S; Delker S; Kreuzpointner R; Kupatt C; Katus HA; Kleinschmidt JA; Boekstegers P; Müller OJ
Gene Ther; 2008 Jan; 15(1):12-7. PubMed ID: 17943147
[TBL] [Abstract][Full Text] [Related]
38. Nuclease-Mediated Gene Therapies for Inherited Metabolic Diseases of the Liver.
Bryson TE; Anglin CM; Bridges PH; Cottle RN
Yale J Biol Med; 2017 Dec; 90(4):553-566. PubMed ID: 29259521
[TBL] [Abstract][Full Text] [Related]
39. Immune responses to AAV vectors: overcoming barriers to successful gene therapy.
Mingozzi F; High KA
Blood; 2013 Jul; 122(1):23-36. PubMed ID: 23596044
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer.
Arjomandnejad M; Dasgupta I; Flotte TR; Keeler AM
BioDrugs; 2023 May; 37(3):311-329. PubMed ID: 36862289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
